Ginkgo Bioworks Holdings, Inc. (DNA) Stock

Ginkgo Bioworks Holdings, Inc. (DNA) is a Healthcare stock trading at $7.39 (as of 2026-08-21), with a market capitalization of $455.98M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Ginkgo Bioworks Holdings, Inc. develops a platform for programming cells to support biological production of products such as therapeutics, food ingredients, and chemical compounds. The company serves multiple end markets including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals, and it has a partnership with Selecta Biosciences on the ImmTOR technology platform.

Understand Ginkgo Bioworks Holdings, Inc.: how it makes money

Ginkgo Bioworks develops a cell programming platform used to program cells to make biological products, and it generates revenue from cell engineering services, foundry work, and biosecurity offerings.

The core profit engine is whether Ginkgo can turn its growing base of active cell engineering programs and platform customers into cell engineering services and foundry revenue, because the cell engineering segment is currently loss-making.

Revenue by segment (latest quarter)
Cell Eng Services$0.0B
Foundry$0.0B
Biosecurity$0.0B

Business quality (Weak): The business is described clearly and the company has relevant operating KPIs (active programs and customers), but the financial snapshot shows very small revenue and a very large operating loss, limiting visibility into sustainable profitability.

Bull case

  • Platform traction signal: Ginkgo reports 138 Active Cell Engineering Programs and 85 Customers with Active Cell Engineering Programs.
  • Multiple revenue streams: The quarter shows revenue contributions across cell engineering services, foundry, and biosecurity.
  • Biosecurity program momentum: Biosecurity revenue is reported as 0.01 USD_B, and biosecurity has active geography with 14 countries having active programs, pilots, or memorandums of understanding.

Bear case

  • Profitability is currently weak: Operating margin is -366.5% and the Cell Engineering Segment Operating Loss is 0.02 USD_B.
  • Biosecurity revenue may be early-stage: Biosecurity Offering Revenue, Biosecurity Product Revenue, and Biosecurity Service Revenue are reported as 0.0 USD_B in the provided candidates.
  • Economics may depend on execution: While there are many active programs, the operating loss suggests high costs relative to the current revenue base.
Valuation — source: SEC EDGAR (first-party)
Price$7.39
Market Cap$455.98M
Price / Book1.03
Price / Sales3.23
FCF Yield-36.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$170.16M
Net Margin-183.8%
Revenue Growth (YoY)-59.7%
EPS Growth (YoY)-17.3%
FCF Growth (YoY)-17.8%
Financial Health — source: SEC EDGAR
Altman Z-Score-7.64 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMETEORA CAPITAL, LLC ($183.65M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOJason Kelly
Employees834
CountryUS
IPO Date2021-04-19

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Editas Medicine, Inc. (EDIT)
  • Ocugen, Inc. (OCGN)
  • Compass Therapeutics, Inc. (CMPX)
  • Voyager Acquisition Corp. (VACH)
  • Lexeo Therapeutics, Inc. Common Stock (LXEO)
  • Fennec Pharmaceuticals Inc. (FENC)
  • X4 Pharmaceuticals, Inc. (XFOR)
  • Palisade Bio, Inc. (PALI)
DNA earnings history · DNA institutional & insider holders · DNA KPIs & operating metrics · DNA financials · DNA investor presentations & press releases · DNA SEC filings · DNA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.